fashion -WSS

fashion

author：leisure time 2025-09-30 05:03:45 - browse：6

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： ASCO Takeaways: Winners, snoozers, and the art of cancer care

focus

WSS

HIV drugs protect against transmission, even in unprotected sex

Intellia reports positive results for its CRISPR

FTC loses bid to block Novant's North Carolina hospital merger

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

A new initiative will help leaders fight the next pandemic

focus

fashion

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ionis drug prevents swelling attacks due to hereditary angioedema

Apple is now the first public company to be valued at $3 trillion

ASCO Daily Recap: CAR

How to save PrEP access — and even expand it

Data don't support strong claims for Covid

Walensky prepares to leave CDC — and Congress — behind

FTC loses bid to block Novant's North Carolina hospital merger

United colonoscopy coverage change 'may cost lives,' doctors say

NIH documents show early flaws of $1.6 billion long Covid program

entertainment

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Shifting the focus from loneliness to social health

FDA's Pazdur wants cancer trials to range beyond China alone

ASCO: AstraZeneca says CAR

Change Healthcare can notify patients about the breach, HHS says

Finland to offer bird flu vaccine to select groups of people, a possible global first

leisure time

focus

leisure time

Wikipedia